Pulmonx (LUNG) Q1 2026: U.S. Treating Centers Expand by 15 as Sales Force Rebuild Drives Transition Year
Pulmonx’s Q1 marks a transitional inflection, with operational focus shifting toward sales force stabilization, disciplined cost control, and targeted market expansion. The company’s near-term trajectory hinges on ramping sales productivity and clinical pipeline execution, with management reiterating full-year growth guidance despite near-term revenue contraction. Investors should watch for sequential improvement in both U.S. and international sales, underpinned by a more focused commercial approach and expense discipline.
Summary
- Sales Force Stabilization Accelerates: U.S. commercial team rebuild and cultural reset are central to growth plans.
- China Drag Masks International Strength: Direct OUS markets show double-digit growth, but China registration delays weigh on reported numbers.
- Cost Discipline Tightens Cash Burn: Restructuring and expense alignment extend cash runway and support margin trajectory.
Performance Analysis
Pulmonx delivered a 9% year-over-year revenue decline in Q1, with total revenue of $20.6 million reflecting ongoing operational transition and external headwinds. U.S. sales fell 7%, but the addition of 15 new treating centers—a quarterly high—signals early traction from the rebuilt commercial team. International revenue dropped 12%, but this was entirely attributable to the absence of China distributor sales due to a pending registration renewal. Excluding China, international markets grew 22% year-over-year, highlighting underlying demand strength in Europe and other geographies.
Gross margin improved to 78%, up 500 basis points year-over-year, driven by a lower mix of lower-margin distributor sales. Operating expenses fell 6% on a reported basis and 8% excluding restructuring and stock-based compensation, reflecting the impact of cost reduction initiatives. Adjusted EBITDA loss improved 18% after normalizing for one-time charges, while cash burn declined meaningfully as Pulmonx ended the quarter with $61.6 million in liquidity and a new $60 million credit facility in place. Management reaffirmed full-year revenue guidance, projecting sequential improvement and a return to growth in the back half of 2026.
- Sales Force Ramp Drives U.S. Reacceleration: New hires are coming up the learning curve, with productivity expected to increase through the year.
- China Registration Delay Creates Optical Drag: Absent China, international growth remains robust, masking underlying momentum.
- Cost Structure Reset Yields Operating Leverage: Expense reduction and restructuring initiatives are lowering cash burn and supporting margin expansion.
The quarter’s results reflect a business in operational transition, with execution in sales force ramp and cost control setting the stage for a potential growth reacceleration in the second half of 2026.
Executive Commentary
"We have filled with top talent all our sales leadership positions and substantially all our U.S. field sales roles. We are also seeing clear improvements in our commercial team culture. Further, sales turnover has stabilized over the last six months, a marked improvement from earlier in 2025."
Glenn French, President and Chief Executive Officer
"We executed a cost restructuring initiative that reduced our ongoing operating expenses by over 10%. With these measures in place, we expect to burn roughly $23 million of cash for the full year 2026, which would be a substantial decrease from the $32 million of cash that we burned in 2025."
Derek Sung, Chief Operating Officer and Chief Financial Officer
Strategic Positioning
1. U.S. Commercial Organization Reset
Pulmonx’s core U.S. business, which accounts for the majority of revenue, is undergoing a deliberate reset. The company has rebuilt its sales force, filled leadership and field roles with experienced talent, and stabilized turnover. The focus is on a “near-to-far” strategy: building high-quality valve programs, targeting COPD clinicians, and aligning hospital resources to drive more consistent patient flow. Management expects this disciplined approach and cultural shift to yield improved sales productivity as 2026 progresses.
2. International Momentum Ex-China
International growth, excluding China, remains a bright spot, with European markets and other direct OUS regions growing double digits. The current revenue contraction is due to the absence of China distributor sales as the company awaits registration renewal. Management expects a gradual resumption of China sales in the second half, but the underlying international business is already showing strong execution and is expected to drive growth once the China drag abates.
3. Cost Alignment and Cash Preservation
Cost discipline is a central pillar of Pulmonx’s turnaround, with operating expenses reduced by over 10% following a restructuring initiative. The company is targeting $23 million in cash burn for 2026, down from $32 million last year, and has secured a new $60 million credit facility to extend its runway. This financial discipline is intended to support ongoing investments in growth drivers while reducing risk and increasing operating leverage.
4. Pipeline and TAM Expansion
The AeroSeal program, Pulmonx’s next-generation clinical initiative, is progressing on track, with the CONVERT II pivotal trial expected to complete enrollment in 2027. AeroSeal could expand the company’s total addressable market (TAM) by approximately 20% globally, serving as both a revenue growth engine and a market expander for Zephyr valves, the company’s flagship product for severe emphysema.
5. Focused Product Strategy
Pulmonx is narrowing its commercial focus, prioritizing high-impact activities and de-emphasizing lower ROI programs such as lung tracts detect in accounts where the fit is not optimal. This targeted approach is designed to maximize returns and accelerate adoption in the most promising centers, while new account onboarding standards have been raised to ensure immediate procedural readiness and engagement.
Key Considerations
This quarter marks a pivotal transition for Pulmonx, as management seeks to restore growth and profitability through commercial discipline, operational focus, and cost management. The following considerations are central to the investment thesis:
- Sales Productivity Lag: With a rebuilt sales force, productivity will ramp gradually, with full impact expected in the second half of 2026.
- China Certification Risk: The timing of China registration renewal remains a potential swing factor, but management expects only gradual contribution upon resumption.
- Expense Management Execution: Sustained cost discipline is required to maintain margin gains and extend cash runway, especially as growth investments continue.
- Pipeline-Driven TAM Expansion: Success in the AeroSeal program is critical for medium-term growth and market expansion.
- Channel and Account Mix: Focus on top-performing and new accounts should drive higher quality revenue, but execution risk remains as new centers ramp.
Risks
Pulmonx faces execution risk as it ramps a largely new sales force and seeks to re-accelerate U.S. growth. Delays in China registration renewal could further depress reported international revenue, while cost discipline must be maintained amid ongoing investments. Pipeline execution, particularly for AeroSeal, presents clinical and regulatory uncertainty, and the company’s ability to sustain double-digit growth exiting 2026 is not yet proven.
Forward Outlook
For Q2 2026, Pulmonx guided to:
- Sequential improvement in year-over-year revenue, with U.S. and international growth rates expected to turn positive in the back half.
- Gross margin to remain around 75% for the year, trending higher in the first half and lower in the second half as distributor sales mix shifts.
For full-year 2026, management reiterated revenue guidance of $90 to $92 million, with:
- Operating expenses targeted at $113 to $115 million, inclusive of $19 million in non-cash stock compensation.
- Cash burn expected to be approximately $23 million for the year.
Management highlighted confidence in sequential improvement, productivity ramp from new sales hires, and ongoing strength in direct international markets. The outlook assumes no significant China contribution in the second half, with gradual resumption upon registration renewal.
Takeaways
Pulmonx’s Q1 underscores a transition year, with the company’s growth trajectory hinging on commercial execution, cost discipline, and pipeline progress.
- Sales Force Rebuild Is Foundational: Stabilizing and ramping the U.S. commercial team is critical for a return to growth and improved operating leverage.
- International Strength Is Underappreciated: Excluding China, direct markets are delivering robust growth, setting the stage for a stronger second half as comps normalize.
- Pipeline and TAM Expansion Remain Key Levers: AeroSeal progress and disciplined account onboarding are essential for sustaining double-digit growth into 2027 and beyond.
Conclusion
Pulmonx’s Q1 2026 results reflect a business in operational transition, with early signs of stabilization in the U.S. sales force, disciplined cost control, and strong underlying international demand. The path to growth reacceleration is contingent on successful execution of commercial and pipeline initiatives, with the second half of 2026 positioned as a key inflection point.
Industry Read-Through
Pulmonx’s experience highlights the critical importance of sales force stability, targeted commercial execution, and disciplined expense management for medtech companies navigating operational resets. The impact of regulatory delays in China underscores the need for diversified geographic revenue streams. For the broader medical device sector, robust demand in direct international markets and the focus on TAM-expanding clinical programs are likely to remain key growth drivers, while operational discipline and cash preservation will be increasingly scrutinized in a volatile funding environment. Investors should monitor how peers manage sales force transitions and pipeline execution amid similar headwinds.